VolitionRx (VNRX) Stock Price, News & Analysis

Company Overview

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

Key Stats

• Today's Range: $0.72 to $0.80
• 50-Day Range: $0.42 to $0.92
• 52-Week Range: $0.40 to $0.94
• Volume: 50,764 shs
• Average Volume: 204,893 shs
• Market Capitalization: $75.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Buy

VolitionRx Stock Analysis - MarketRank™

VolitionRx scored higher than 32% of companies evaluated by MarketBeat, and ranked 743rd out of 931 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

VolitionRx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

VolitionRx has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of VolitionRx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of VolitionRx is -2.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for VNRX.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

VolitionRx does not currently pay a dividend.

Dividend Growth

VolitionRx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for VNRX.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for VNRX on MarketBeat in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, VolitionRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $148,475.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

10.40% of the stock of VolitionRx is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 8.09% of the stock of VolitionRx is held by institutions.

VNRX Stock Analysis - Frequently Asked Questions

How have VNRX shares performed this year?

VolitionRx's stock was trading at $0.60 at the start of the year. Since then, VNRX shares have increased by 28.6% and is now trading at $0.7718.
View the best growth stocks for 2025 here.

How were VolitionRx's earnings last quarter?

VolitionRx Limited (NYSE:VNRX) announced its quarterly earnings results on Monday, March, 25th. The company reported ($0.11) EPS for the quarter. The business earned $0.24 million during the quarter, compared to the consensus estimate of $0.50 million.

Who are VolitionRx's major shareholders?

VolitionRx's top institutional investors include Armistice Capital LLC (8.14%). Insiders that own company stock include Cameron John Reynolds, Martin Charles Faulkes, Guy Archibald Innes, Jacob Vincent Micallef, Corp Ltd Eight, Gaetan Michel, Salvatore Thomas Butera, Rodney Gerard Rootsaert and Phillip Barnes.
View institutional ownership trends.

How do I buy shares of VolitionRx?

Shares of VNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of VolitionRx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that VolitionRx investors own include BlackRock Innovation and Growth Term Trust (BIGZ), FS KKR Capital (FSK), Guggenheim Strategic Opportunities Fund (GOF), 3M (MMM), OFS Credit (OCCI), XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 3/25/2024
• Today: 6/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:VNRX
• CIK: 93314
• Web: N/A
• Phone: 646-650-1351
• Fax: 65 32 8172 5651
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $3.50
• High Stock Price Target: $5.00
• Low Stock Price Target: $2.50
• Potential Upside/Downside: +353.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$35.32 million
• Net Margins: -2,321.14%
• Pretax Margin: -2,346.62%
• Return on Equity: N/A
• Return on Assets: -163.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $1.31 million
• Price / Sales: 60.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.11) per share
• Price / Book: -7.02

Miscellaneous

• Outstanding Shares: 103,023,000
• Free Float: 80,804,000
• Market Cap: $79.51 million
• Optionable: Optionable
• Beta: 1.07